摘要
安罗替尼是一种新型的多靶点小分子酪氨酸激酶抑制剂(TKI),它通过抑制血管内皮生长因子受体(VEGFR)而发挥抗肿瘤血管生成的作用。然而,血管内皮生长因子(VEGF)信号通路(VSP)的阻滞会导致相关不良反应(AEs)的发生,高血压为其常见的AEs之一。本文针对安罗替尼致高血压的发生状况、发生机制、危险因素、管理及其与抗肿瘤疗效的关系等内容进行综述,为相关肿瘤患者的药物治疗提供参考。
Anlotinib is a novel small-molecule multitarget tyrosine kinase inhibitor(TKI) that acts as an anti-tumor angiogenesis agent by inhibiting vascular endothelial growth factor receptor(VEGFR). However, blockage of the VEGF signaling pathway(VSP) leads to the development of adverse effects(AEs), and hypertension is one of the common AEs. This review summarized updated information about the occurrence, mechanism, risk factors, management of hypertension induced by anlotinib and its relationship with antitumor efficacy, so as to provide reference for drug treatment of tumor patients and ultimately bring benefit to them.
作者
张莉
邢亚群
江洁美
夏泉
ZHANG Li;XING Ya-qun;JIANG Jie-mei;XIA Quan(Department of Pharmacy,the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233040,China;Department of Pharmacy,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第20期2351-2357,共7页
Chinese Journal of New Drugs
关键词
安罗替尼
高血压
不良反应
血管内皮生长因子受体
anlotinib
hypertension
adverse effects
vascular endothelial growth factor receptor(VEGFR)
